by Sai Life Sciences Share Price Target 2025 to 2040 : Sai Life Sciences Limited is a premier contract research and manufacturing organization (CRMO), offering its services to pharmaceutical, biotechnology and life science sectors. Specializing in drug discovery, development and manufacturing for global pharmaceutical companies. Here’s more information on their Stock Price Target 2025-2040.
Sai Life Sciences Company Overview
Sai Life Sciences Ltd, established in Hyderabad in 1999, has emerged as a prominent player in the pharmaceutical industry. Over its 16 year existence, this Hyderabad-based firm has built up an outstanding reputation for offering high-quality drug discovery, development, and manufacturing services to global pharmaceutical innovators. Led by K. Ranga Raju as Chairman, Sai Life Sciences has become a valued partner to some of the world’s premier pharmaceutical firms; listed both on National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), reflecting robust market presence and financial strength; for more information please visit sailife.com
Recent Graph of Sai Life Sciences
Sai Life Sciences Fundamental Analysis
| Attribute | Value |
|---|---|
| Open | 656.00 |
| Previous Close | 656.80 |
| Volume | 124,596 |
| Value (Lacs) | 816.60 |
| VWAP | 660.92 |
| Beta | 1.40 |
| Market Cap (Rs. Cr.) | 13,631 |
| High | 675.05 |
| Low | 651.00 |
| UC Limit | 788.15 |
| LC Limit | 525.45 |
| 52 Week High | 808.80 |
| 52 Week Low | 646.95 |
| Face Value | 1 |
| All Time High | 808.80 |
| All Time Low | 646.95 |
| 20D Avg Volume | 0 |
| 20D Avg Delivery (%) | — |
| Book Value Per Share | 48.24 |
| Dividend Yield | — |
See More : Future of Punjab and Sind Bank Shares: 2025–2030 Price Predictions
Sai Life Sciences Financials
Income Statement
- Revenue increased 20.38% year-on-year (Y/Y).
- Operating expenses amounted to an impressive INR 8.08 billion in 2014-15 – an 18-18% rise year-on-year.
- Net income increased significantly year over year by 729.00% to INR 828.09 Million.
- Net profit margin stood at 5.65%, representing an amazing 589.02% improvement from 2015.
- EBITDA saw significant growth, reaching INR 2.45 billion, an increase of 94.52% year over year.
- For the year 2017, the effective tax rate was 24.19%.
- However, earnings per share (EPS) data were not provided for this period.
Balance Sheet
- Cash and Short-Term Investments: INR 1.85 billion, representing a decrease of 9.888% year-on-year.
- Total Assets: INR 22.75 billion, representing a 4.05 % increase.
- Total Liabilities: INR 13.00 billion, which represents an increase of 0.11% year-on-year.
- Total Equity is INR 9.75 billion, unchanged since 2016.
- Outstanding Shares of Common Stock (as at October 2018): 183.92 million, representing no change from year-ago levels.
- Price to Book Ratio (PCBR): 13.83 (constant).
- Return on Assets (ROA): 4.83% without fluctuations.
- Return on Capital (ROC): 5.78%, which remains steady compared to last year.
Cash Flow
- Net Income was INR 828.09 million – representing an impressive increase of 729.00% year-on-year.
- Cash from Operations has increased by 19.91% year over year to INR 2.63 billion.
- Cash from Investing Activities: INR-1.92 billion, representing an 89.01% decrease.
- Cash from Financing Activities: INR-952.99 Million (an increase of 52.50% over previous outflows).
- Cash balance change was INR-235.60 million, representing an improvement of 70.64% while remaining negative.
- Free Cash Flow was reduced by INR 254.97 Million or 1,211.34% year over year.
Sai Life Sciences Share Price Target 2025
Sai Life Sciences shares may go up or down over time; according to our analysis levels, its minimum price could reach Rs700 in 2025 while its maximum could hit Rs930.
| Month Wise (Year 2025) | Target Price |
|---|---|
| January | ₹700 |
| February | ₹721 |
| March | ₹730 |
| April | ₹746 |
| May | ₹760 |
| June | ₹778 |
| July | ₹796 |
| August | ₹830 |
| September | ₹855 |
| October | ₹880 |
| November | ₹905 |
| December | ₹930 |
Sai Life Sciences Share Price Target 2026
Sai Life Sciences stock may experience upward and downward movement over the coming decade, according to our analysis levels, wherein minimum prices may range between Rs950-1.100 in 2026.
| Month Wise (Year 2026) | Target Price |
|---|---|
| January | ₹950 |
| December | ₹1100 |
Sai Life Sciences Share Price Target 2030
Share prices of Sai Life Sciences can fluctuate up and down over time. According to our analysis levels, their shares could fall as low as Rs1,750 while reaching as high as Rs2,150 by 2030.
| Month Wise (Year 2030) | Target Price |
|---|---|
| January | ₹1750 |
| December | ₹2150 |
Sai Life Sciences Share Price Target 2040
Sai Life Sciences share prices may fluctuate widely over time. According to our analysis levels, their minimum share price could fall as low as Rs4,500 while reaching as far up as Rs5,650 by 2040.
| Month Wise (Year 2040) | Target Price |
|---|---|
| January | ₹4500 |
| December | ₹5650 |
Sai Life Sciences Share Price Target 2050
Sai Life Sciences share price may fluctuate widely over time. According to our analysis levels, their minimum share price in 2050 could drop as far as Rs7,250 while they can go as high as Rs8,000.
| Month Wise (Year 2050) | Target Price |
|---|---|
| January | ₹7250 |
| December | ₹8000 |
Peer comparison
- Torrent Pharma
- Ajanta Pharma
- Gland Pharma
- ERIS Lifescience
- Caplin Point Lab
- Sai Life
- Marksans Pharma
Half Yearly Results
| Parameter | Sep 2023 (INR Cr.) | Sep 2024 (INR Cr.) |
|---|---|---|
| Sales | 642 | 675 |
| Expenses | 578 | 547 |
| Operating Profit | 64 | 128 |
| Operating Profit Margin (OPM) | 10% | 19% |
| Other Income | 14 | 18 |
| Interest | 42 | 42 |
| Depreciation | 57 | 67 |
| Profit Before Tax | -20 | 37 |
| Tax % | -35% | 25% |
| Net Profit | -13 | 28 |
Sales: Sales increased from INR 642 crore to INR 675 crore.
Expenses: Decreased from INR 578 crore to INR 547 crore.
Operating Profit has increased from INR 64 crore to INR 128 crore.
Operating Profit Margin (OPM): Increased from 10% to 19%.
Other Income: Has increased from INR 14 crore to INR 18 crore.
Interest remained steady at INR 42 crore.
Depreciation: Increased from INR 57 crore to INR 67 crore.
Profit Before Tax: Results have improved from an operating loss of INR 20 crore to a profit of INR 37 crore.
Tax: Switched from 35% (tax benefit) to 25% (tax payable).
Net Profit: From an initial loss of INR 13 crore, our profit has now reached INR 28 crore.
Profit & Loss ( Sai Life Sciences Share Price Target 2025 to 2040 )
| Parameter | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Sales | 870 | 1,217 | 1,465 |
| Expenses | 743 | 1,048 | 1,178 |
| Operating Profit | 126 | 169 | 287 |
| Operating Profit Margin (OPM) | 15% | 14% | 20% |
| Other Income | 28 | 27 | 29 |
| Interest | 54 | 81 | 88 |
| Depreciation | 90 | 99 | 119 |
| Profit Before Tax | 10 | 16 | 109 |
| Tax % | 36% | 39% | 24% |
| Net Profit | 6 | 10 | 83 |
| EPS in Rs | — | — | — |
| Dividend Payout % | 1,117% | 676% | 0% |
Sales for 2024 increased substantially from INR 870 crore in March 2022 to INR 1,465 crore, reflecting steady progress in revenue generation.
expenses also rose, from INR 743 crore in 2022 to INR 1,178 crore in 2024 – in line with sales growth.
Operating Profit witnessed a notable upswing, rising from INR 126 crore in 2022 to INR 287 crore by 2024 and showing improved cost efficiency through an OPM improvement from 15% to 20% during that same time.
Other Income remained relatively consistent over time, from INR 28 crore in 2022 to INR 29 crore by 2024.
Interest Expenses have steadily increased over time, from INR 54 crore in 2022 to INR 88 crore by 2024, reflecting increased borrowing costs.
Depreciation also increased from INR 90 crore to INR 119 crore, reflecting higher capital expenditure and asset amortization costs.
Profit Before Tax improved significantly between 2022 and 2024, from INR 10 crore to INR 109 crore. Tax percentage also saw significant improvements, reaching 24% by 2024 (compared with 36% in 2022) which positively impacted net profits.
Net Profit made an astounding leap, from INR 6 crore in 2022 to INR 83 crore in 2024, reflecting strong financial performance.
Dividend Payout Ratio has decreased from an extremely high 1,117% in 2022 to zero by 2024, suggesting a change in dividend strategy.
Balance Sheet
| Parameter | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|
| Equity Capital | 18 | 18 | 19 |
| Reserves | 870 | 957 | 1,027 |
| Borrowings | 933 | 929 | 992 |
| Other Liabilities | 358 | 359 | 439 |
| Total Liabilities | 2,179 | 2,262 | 2,477 |
| Fixed Assets | 1,037 | 1,180 | 1,228 |
| CWIP | 151 | 107 | 152 |
| Investments | 2 | 2 | 2 |
| Other Assets | 989 | 973 | 1,095 |
| Total Assets | 2,179 | 2,262 | 2,477 |
Shareholding Pattern
| Parameter | Dec 2024 |
|---|---|
| Promoters | 35.24% |
| FIIs (Foreign Institutional Investors) | 11.72% |
| DIIs (Domestic Institutional Investors) | 11.95% |
| Public | 41.08% |
| No. of Shareholders | 1,81,122 |
How To Buy Sai Life Sciences Share?
To purchase Sai Life Sciences shares, use any one of many stock brokers’ trading platforms and purchase directly.
Below is a list of most trading platforms used for purchasing Sai Life Sciences shares.
- Zerodha App
- Upstox App
- Dhan App
- Angel One App
- Phonepe. Share Market App
- Groww App
Conclusion
Sai Life Sciences represents an attractive investment opportunity with strong fundamentals, strategic growth initiatives, and steadily rising healthcare demand – investors may anticipate substantial returns between 2025-2040.
One thought on “Sai Life Sciences Share Price Target 2025 to 2040”